(Alliance News) - Stocks in London rallied on Wednesday despite news of higher inflation, and an expected US rate increase, as oil prices edged lower. Read More
(Alliance News) - Stock prices in London were higher at midday on Friday, after stronger-than-expected UK economic growth offered some encouragement, although elevated energy costs continued to cloud the outlook ahead of key US inflation data. Read More
(Alliance News) - Stock prices in London closed lower on Thursday, as oil prices surged above USD105 and hotter-than-expected US producer inflation fuelled concerns, while the European Central Bank raised interest rates as expected. Read More
(Alliance News) - London's FTSE 100 faded into the close on Wednesday, posting modest losses, as a strong US inflation print knocked sentiment ahead of Nvidia earnings. Read More
(Alliance News) - The FTSE 100 closed higher on Tuesday as oil prices fell and investors geared up for Wednesday's double bill of earnings from Nvidia and US inflation data. Read More
(Alliance News) - The FTSE 100 closed lower on Tuesday with gains in oil stocks, amid ongoing uncertainty in the Middle East, offset by caution ahead of US inflation data and weak insurers. Read More
(Alliance News) - The FTSE 100 made strong progress on Tuesday, buoyed by positive earnings and a drop in the oil price, which helped shrug off worries sparked by a chip sector sell-off in Asia. Read More
(Alliance News) - Compass Group PLC on Tuesday affirmed its confidence in the company's full-year prospects, backed by sales growth in the third quarter. Read More
(Alliance News) - The FTSE 100 was called lower on Tuesday, while the pound continues to strengthen, following the release of UK unemployment, earnings and borrowing data. Read More
(Alliance News) - London's FTSE 100 nudged higher on Tuesday, outperforming European and US peers, despite fresh falls among technology stocks and renewed tension in the Middle East. Read More
(Alliance News) - The FTSE 100 gave back early gains on Monday as falls in gold miners and AstraZeneca, plus soft construction figures, dampened early enthusiasm. Read More
